Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

A. M. Tsimberidou, H. M. Kantarjian, E. Estey, J. E. Cortes, S. Verstovsek, S. Faderl, D. A. Thomas, G. Garcia-Manero, A. Ferrajoli, J. T. Manning, M. J. Keating, M. Albitar, S. O'Brien, F. J. Giles

Research output: Contribution to journalArticle

Abstract

Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002. In all, 21 patients with nonleukemic GS, 1520 patients with acute myeloid leukemia (AML), and 402 patients with high-risk myelodysplastic syndrome (MDS) were identified. GS occurred in 1.4% of patients with AML, and 1.1% of patients with AML or high-risk MDSs. The median patient age was 57 years (range, 7-81). Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities. The median follow-up of surviving patients is 12 months (range, 7-75). In all, 20 patients were treated. Patients were treated with AML-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1). A total of 13 patients (65%) achieved complete remission and one patient (5%) achieved partial remission. The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required.

Original languageEnglish (US)
Pages (from-to)1100-1103
Number of pages4
JournalLeukemia
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Myeloid Sarcoma
Radiotherapy
Drug Therapy
Acute Myeloid Leukemia
Chromosomes, Human, Pair 8
Survival
Chromosome Aberrations

Keywords

  • Cytogenetics
  • Granulocytic sarcoma
  • Survival
  • Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Tsimberidou, A. M., Kantarjian, H. M., Estey, E., Cortes, J. E., Verstovsek, S., Faderl, S., ... Giles, F. J. (2003). Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia, 17(6), 1100-1103. https://doi.org/10.1038/sj.leu.2402958

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. / Tsimberidou, A. M.; Kantarjian, H. M.; Estey, E.; Cortes, J. E.; Verstovsek, S.; Faderl, S.; Thomas, D. A.; Garcia-Manero, G.; Ferrajoli, A.; Manning, J. T.; Keating, M. J.; Albitar, M.; O'Brien, S.; Giles, F. J.

In: Leukemia, Vol. 17, No. 6, 01.06.2003, p. 1100-1103.

Research output: Contribution to journalArticle

Tsimberidou, AM, Kantarjian, HM, Estey, E, Cortes, JE, Verstovsek, S, Faderl, S, Thomas, DA, Garcia-Manero, G, Ferrajoli, A, Manning, JT, Keating, MJ, Albitar, M, O'Brien, S & Giles, FJ 2003, 'Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy', Leukemia, vol. 17, no. 6, pp. 1100-1103. https://doi.org/10.1038/sj.leu.2402958
Tsimberidou, A. M. ; Kantarjian, H. M. ; Estey, E. ; Cortes, J. E. ; Verstovsek, S. ; Faderl, S. ; Thomas, D. A. ; Garcia-Manero, G. ; Ferrajoli, A. ; Manning, J. T. ; Keating, M. J. ; Albitar, M. ; O'Brien, S. ; Giles, F. J. / Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. In: Leukemia. 2003 ; Vol. 17, No. 6. pp. 1100-1103.
@article{93fb6e5ec63049579d14d582f6fafa06,
title = "Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy",
abstract = "Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002. In all, 21 patients with nonleukemic GS, 1520 patients with acute myeloid leukemia (AML), and 402 patients with high-risk myelodysplastic syndrome (MDS) were identified. GS occurred in 1.4{\%} of patients with AML, and 1.1{\%} of patients with AML or high-risk MDSs. The median patient age was 57 years (range, 7-81). Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities. The median follow-up of surviving patients is 12 months (range, 7-75). In all, 20 patients were treated. Patients were treated with AML-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1). A total of 13 patients (65{\%}) achieved complete remission and one patient (5{\%}) achieved partial remission. The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required.",
keywords = "Cytogenetics, Granulocytic sarcoma, Survival, Therapy",
author = "Tsimberidou, {A. M.} and Kantarjian, {H. M.} and E. Estey and Cortes, {J. E.} and S. Verstovsek and S. Faderl and Thomas, {D. A.} and G. Garcia-Manero and A. Ferrajoli and Manning, {J. T.} and Keating, {M. J.} and M. Albitar and S. O'Brien and Giles, {F. J.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1038/sj.leu.2402958",
language = "English (US)",
volume = "17",
pages = "1100--1103",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

AU - Tsimberidou, A. M.

AU - Kantarjian, H. M.

AU - Estey, E.

AU - Cortes, J. E.

AU - Verstovsek, S.

AU - Faderl, S.

AU - Thomas, D. A.

AU - Garcia-Manero, G.

AU - Ferrajoli, A.

AU - Manning, J. T.

AU - Keating, M. J.

AU - Albitar, M.

AU - O'Brien, S.

AU - Giles, F. J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002. In all, 21 patients with nonleukemic GS, 1520 patients with acute myeloid leukemia (AML), and 402 patients with high-risk myelodysplastic syndrome (MDS) were identified. GS occurred in 1.4% of patients with AML, and 1.1% of patients with AML or high-risk MDSs. The median patient age was 57 years (range, 7-81). Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities. The median follow-up of surviving patients is 12 months (range, 7-75). In all, 20 patients were treated. Patients were treated with AML-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1). A total of 13 patients (65%) achieved complete remission and one patient (5%) achieved partial remission. The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required.

AB - Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency, presenting characteristics, and survival in patients with nonleukemic GS by conducting a review of all untreated patients presenting to the MD Anderson Cancer Center between January 1990 and June 2002. In all, 21 patients with nonleukemic GS, 1520 patients with acute myeloid leukemia (AML), and 402 patients with high-risk myelodysplastic syndrome (MDS) were identified. GS occurred in 1.4% of patients with AML, and 1.1% of patients with AML or high-risk MDSs. The median patient age was 57 years (range, 7-81). Among 20 patients with available cytogenetics in tissue and/or bone marrow, six had chromosome 8 abnormalities. The median follow-up of surviving patients is 12 months (range, 7-75). In all, 20 patients were treated. Patients were treated with AML-type chemotherapy (n=16), chemotherapy and radiotherapy (n=3), or radiotherapy alone (n=1). A total of 13 patients (65%) achieved complete remission and one patient (5%) achieved partial remission. The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required.

KW - Cytogenetics

KW - Granulocytic sarcoma

KW - Survival

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0038683184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038683184&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402958

DO - 10.1038/sj.leu.2402958

M3 - Article

C2 - 12764375

AN - SCOPUS:0038683184

VL - 17

SP - 1100

EP - 1103

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -